about
Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary HypertensionHypertension crisisThe ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?Blood pressure response to catheter-based renal sympathetic denervation in severe resistant hypertension: data from the Greek Renal Denervation Registry.Renal sympathetic denervation and systemic hypertension.Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository.Benefits from treatment and control of patients with resistant hypertension.Common secondary causes of resistant hypertension and rational for treatmentImpact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension.Comparative prognostic value of systolic, diastolic, and pulse pressure.Cardiovascular risk assessment and triptans.Candesartan cilexetil in cardiovascular disease.Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension.Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.Aggressive blood pressure control and stroke prevention: role of calcium channel blockers.Beta-blockers in the management of hypertension: focus on nebivolol.Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence.On target to dual block RAS?Hypertrophic and hypertensive hypertrophic cardiomyopathy--a true association?Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions.Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions.Drug therapy for the patient with resistant hypertension.Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model.Renal Sympathetic Denervation: Hibernation or Resurrection?Device-Based Therapy for Drug-Resistant Hypertension: An Update.Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTN I first-in-human study using a multi-electrode ablation system.The modulatory effect of exogenously added prostaglandin E1 or E2 on the delayed-type hypersensitivity reaction of normal or tumored mice.Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies.Relation of impaired coronary microcirculation to increased urine albumin excretion in patients with systemic hypertension and no epicardial coronary arterial narrowing.Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias.Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension.
P50
Q26766213-30EBB149-E4AB-46F1-858E-1673EBEDAD24Q28283519-87E97A61-B3F7-4449-BACC-D16B511E39DCQ31111887-000CCEAE-F79B-4705-967C-CFB4164C9FE1Q31148433-66611651-0A87-4DD7-8DB1-844338E1A308Q34098483-8581687B-CB27-44E3-94C7-1F4C0C012D9BQ34239533-FB3C5149-D903-47EA-9246-5B709CE41566Q34460638-C1476728-0713-4E44-AF25-2561CD94323BQ34669789-B6FD46EA-63C7-45E0-A41B-75A7064C0ECAQ34921180-26C94D8A-0A80-4EB3-BA9C-595E58CDE5FAQ34985314-28963172-E04D-453D-AEA9-124169EECEB2Q35066109-96F4E37C-8A96-4D4F-B184-B43B865A52DDQ35776431-74D247B3-5987-428C-93EE-6B04E3FD379CQ35925682-50B75D24-F892-42E5-AB4F-2669EB48623AQ36027039-2B747A46-6BB1-493D-B416-A7F3C3831789Q36425956-3AE2DD5B-8107-4CA4-A4E3-1EDE2CF15B4CQ37029407-3F4B6274-8E75-4C56-A7FF-4E185A48E93CQ37132664-490AB78C-BCFF-4D4D-83D1-CE362EFB4C38Q37134471-C9F68F3F-4EDF-44FA-81D7-E09A4A7B1ECBQ37333256-0E04A345-A029-4301-BDFD-B9FEFC8623C8Q37368669-136314BE-4F05-4749-BA2B-F1E612398225Q37400402-4F81D576-A54B-4CA4-B055-8F585956419DQ37486992-C7175781-31FB-4B93-BECD-2CBDCE5D9B2EQ37597024-0F8040F4-DE60-4C2C-9323-F8F43B7AB0F9Q38183509-EB2DC53B-6F38-485F-A928-9E67DACB0B29Q38200958-C11DC8A4-7D26-4218-BF75-870CEED36780Q38373858-F8C60E4E-435D-47AC-A5BA-495F5BC20626Q38412937-3DBC37D5-3C58-42A4-9884-09966137157AQ38854859-97A3D673-96A1-450D-A468-CE222180A6FDQ38893138-9D87DA74-DA6C-4D75-B695-AB8E7B78D7C0Q40421283-5C6E901D-7EF3-4325-B4C3-E7F6A4BC2E5BQ40461830-1AF66982-45CE-40F0-8C14-6B916B73E27FQ40602005-19A65865-780B-4DD6-AFE7-07D2F2A18C73Q40613472-15A6A7C3-0095-4DC8-8EEA-26B017605B44Q41218678-12213FD1-0893-444C-A610-9231D78EA043Q41291894-BC38C221-BA3C-4559-A595-3DF74947146CQ41876079-43FAFB21-D030-44F4-A880-1DCB61D222D0Q41978032-8E2B8FF4-4D01-4A68-98BC-F3856CC6E10CQ42164940-64A36EDA-8D3C-423B-96E6-718F97016C71Q42243640-7A06B7DD-C479-437A-9178-D7080888F0F7Q42250631-CB308CE5-E61C-4590-98BC-4F28C6AC8BA3
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vasilios Papademetriou
@ast
Vasilios Papademetriou
@en
Vasilios Papademetriou
@es
Vasilios Papademetriou
@nl
Vasilios Papademetriou
@sl
type
label
Vasilios Papademetriou
@ast
Vasilios Papademetriou
@en
Vasilios Papademetriou
@es
Vasilios Papademetriou
@nl
Vasilios Papademetriou
@sl
prefLabel
Vasilios Papademetriou
@ast
Vasilios Papademetriou
@en
Vasilios Papademetriou
@es
Vasilios Papademetriou
@nl
Vasilios Papademetriou
@sl
P106
P1153
55410626900
P21
P31
P496
0000-0002-2882-2757